Circulating fatty acids and risk of coronary heart disease and stroke:Individual participant data meta-analysis in up to 16,126 participants by Borges, Maria Carolina et al.
                          Borges, M. C., Lawlor, D. A., Gaunt, T. R., Ben-Shlomo, Y., & al., E.
(2020). Circulating fatty acids and risk of coronary heart disease and
stroke: Individual participant data meta-analysis in up to 16,126
participants. Journal of the American Heart Association, 9(5),
[e013131]. https://doi.org/10.1161/JAHA.119.013131
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1161/JAHA.119.013131
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via American Heart
Association at https://www.ahajournals.org/doi/10.1161/JAHA.119.013131 . Please refer to any applicable terms
of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Circulating Fatty Acids and Risk of Coronary Heart Disease and
Stroke: Individual Participant Data Meta-Analysis in Up to 16 126
Participants
Maria Carolina Borges, PhD; Amand Floriaan Schmidt, PhD; Barbara Jefferis, PhD; S. Goya Wannamethee, PhD; Debbie A. Lawlor, PhD;
Mika Kivimaki, PhD; Meena Kumari, PhD; Tom R. Gaunt, PhD; Yoav Ben-Shlomo, PhD; Therese Tillin, MSc; Usha Menon, MD;
Rui Providencia, MD; Caroline Dale, PhD; Aleksandra Gentry-Maharaj, PhD; Alun Hughes, PhD; Nish Chaturvedi, MD;
Juan Pablo Casas, PhD;* Aroon D. Hingorani, PhD;* on behalf of the UCLEB Consortium**
Background-—We aimed at investigating the association of circulating fatty acids with coronary heart disease (CHD) and stroke risk.
Methods and Results-—We conducted an individual-participant data meta-analysis of 5 UK-based cohorts and 1 matched case-
control study. Fatty acids (ie, omega-3 docosahexaenoic acid, omega-6 linoleic acid, monounsaturated and saturated fatty acids)
were measured at baseline using an automated high-throughput serum nuclear magnetic resonance metabolomics platform. Data
from 3022 incident CHD cases (13 104 controls) and 1606 incident stroke cases (13 369 controls) were included. Logistic
regression was used to model the relation between fatty acids and odds of CHD and stroke, adjusting for demographic and lifestyle
variables only (ie, minimally adjusted model) or with further adjustment for other fatty acids (ie, fully adjusted model). Although
circulating docosahexaenoic acid, but not linoleic acid, was related to lower CHD risk in the fully adjusted model (odds ratio, 0.85;
95% CI, 0.76–0.95 per standard unit of docosahexaenoic acid), there was evidence of high between-study heterogeneity and effect
modification by study design. Stroke risk was consistently lower with increasing circulating linoleic acid (odds ratio for fully
adjusted model, 0.82; 95% CI, 0.75–0.90). Circulating monounsaturated fatty acids were associated with higher CHD risk across all
models and with stroke risk in the fully adjusted model (odds ratio, 1.22; 95% CI, 1.03–1.44). Saturated fatty acids were not related
to increased CHD risk in the fully adjusted model (odds ratio, 0.94; 95% CI, 0.82–1.09), or stroke risk.
Conclusions-—We found consistent evidence that linoleic acidwas associatedwith decreased risk of stroke and thatmonounsaturated
fatty acidswere associatedwith increased risk of CHD. The different pattern betweenCHDand stroke in terms of fatty acids risk profile
suggests future studies should be cautious about using composite events. Different study designs are needed to assesswhich, if any, of
the associations observed is causal. ( J Am Heart Assoc. 2020;9:e013131. DOI: 10.1161/JAHA.119.013131.)
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E arly interest in the relation of dietary fatty acids withcardiovascular disease emerged following results from
ecological studies conducted between the 1950s and 1970s.
These studies indicated that populations with high consump-
tion of saturated fatty acids (SFAs) had increased rates of
mortality from cardiovascular diseases,1 while reduced
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cardiovascular disease mortality was observed in populations
with high consumption of omega-3 polyunsaturated fatty
acids.2,3 Numerous subsequent controlled feeding studies
showed that dietary fatty acid composition could modulate
the concentration of the major circulating blood lipid fractions
(mainly total, low-density lipoprotein cholesterol, and high-
density lipoprotein cholesterol and triacylglycerols).4 These
observations played a central role in the classical diet-heart
hypothesis and have prompted recommendations on dietary
fatty acid intake for primary and secondary prevention of
cardiovascular diseases.5–7
In the past few decades, however, some long-lasting
beliefs concerning the effects of fatty acids on health have
been challenged. For example, it has been argued that the
effect of reduction of dietary SFAs on coronary heart disease
(CHD) may depend on what dietary components they replace
(carbohydrates or polyunsaturated fatty acids).8 In addition,
systematic reviews of randomized controlled trials (RCTs)
reported heterogeneous results regarding the protective
effect of omega-3 fatty acids on cardiovascular outcomes
with more recent trials failing to replicate initial positive
findings.9–13 The reasons for inconsistent findings remain
elusive, although several methodological issues may have
contributed to heterogeneity in both RCTs and observational
studies. In the case of omega-3, a recent systematic review of
RCTs that lasted at least 12 months (n=112 059 participants)
concluded that increasing omega-3 intake has little or no
effect on cardiovascular events or mortality and found no
evidence of differential effects according to omega-3 dose,
trial duration, and primary or secondary prevention.13 For
other fatty acids, evidence is less convincing.14 Furthermore,
most studies have focused on CHD as the outcome; hence,
the relevance of most fatty acids for cerebrovascular disease
remains unclear.
We therefore performed an individual-participant data
meta-analysis to assess the association of several circulating
fatty acids with both CHD and stroke risk by (1) including data
from 6 UK-based studies with a focus on primary events and
information on multiple confounders; (2) using objectively
measured blood fatty acid concentration, which reflects
dietary intake and biological processes (eg, absorption and
metabolism); (3) investigating potential methodological and
biological sources of heterogeneity (sex, ethnicity, age,




Individual data were available on 23 518 participants from 6
UK-based studies (5 cohorts and 1 nested case-control study)
participating in the UCL-LSHTM-Edinburgh-Bristol (UCLEB)
consortium15: BWHHS (British Women’s Heart and Health
Study),16 BRHS (British Regional Heart Study),17 WHII (White-
hall-II Study),18 the SABRE (Southall and Brent Revisited)19
cohort, CaPS (Caerphilly Prospective Study),20 and a case-
control study nested in the UKCTOCS (United Kingdom
Collaborative Trial of Ovarian Cancer Screening)21 (Table 1).
All participating studies obtained informed consent from
participants and received ethical approval. Because of the
sensitive nature of the data collected for this study, requests
to access UCLEB data sets from qualified researchers trained
in human subject confidentiality protocols may be sent to the
UCLEB steering committee at a.hingorani@ucl.ac.uk.15
Ascertainment of Coronary Heart Disease and
Stroke
CHD was defined as incident nonfatal myocardial infarction,
revascularization procedure (coronary artery bypass surgery
or angioplasty), or fatal CHD (International Classification of
Diseases, Tenth Revision (ICD-10) codes I20–I25, I51.6).
Stroke was defined as incident nonfatal ischemic, hemor-
rhagic stroke (excluding transient ischemic attack) or fatal
stroke (International Classification of Diseases, Tenth Revision
(ICD-10) codes I60.x, I61.x, I62, I62.9 I63.x, I64.x, I65.x, I66.x,
I67, I67.2, I67.8, I67.9, I69.x, G46.x, G45.0, G45.1, G45.2,
G45.3) (Table 1). Subjects with a prior history of CHD or
stroke were excluded from analyses.
Clinical Perspective
What Is New?
• There is inconsistent evidence on the relation of fatty acids
with coronary heart disease (CHD) and stroke risk.
• We performed a large individual-participant data meta-
analysis to assess the association of several circulating fatty
acids with CHD and stroke risk and to investigate potential
sources of inconsistency in the current literature.
What Are the Clinical Implications?
• We found consistent evidence that circulating linoleic acid is
associated with lower risk of stroke and that monounsat-
urated fatty acids are related to higher risk of CHD.
• Our findings do not support that the association of fatty
acids with CHD or stroke risk is nonlinear or modified by
participants’ characteristics (ie, by age group, sex, European
ancestry, body mass index, or severity of event).
• The different pattern between CHD and stroke in terms of
fatty acids risk profile raises a cautionary note for studies in
which composite events are used.
DOI: 10.1161/JAHA.119.013131 Journal of the American Heart Association 2
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Assessment of Fatty Acids
Fatty acids were assayed using an automated high-throughput
serum nuclear magnetic resonance metabolomics platform
that quantifies 233 metabolic markers, including fatty acids,
lipoprotein subclasses, a-1 acid glycoprotein, amino acids,
glycolysis-related measures, and ketone bodies (Nightingale
Health Ltd., Helsinki, Finland). The fatty acids available in the
nuclear magnetic resonance platform used in the current
study were the long-chain omega-3 docosahexaenoic acid
22:6 (DHA), the omega-6 linoleic acid 18:2 (LA), total
monounsaturated fatty acids (MUFAs), and total SFAs. The
quantified fatty acids correspond to all forms of fatty acids
present in the circulation (ie, all the fatty acids in triglycerides,
phospholipids, or cholesterol esters, or as free fatty
acids). Nuclear magnetic resonance data preprocessing
and quantification were as described previously22–27 and in
Data S1.
Covariates
Baseline information at the time fatty acids were measured
included demographic variables (sex, age [in years], and
ethnicity [European, Indian Asian, African Caribbeans, or
other]); and lifestyle characteristics (measured body mass
index [BMI; kg/m2], smoking [never or ever], and alcohol
drinking [never or ever]). Data on smoking and alcohol
drinking at baseline were not available for UKCTOCS nested
case-control study.
Statistical Analysis
All fatty acids measures were converted to study- and sex-
specific Z scores (ie, standardized and centered to have a
mean of 0 and a unit of 1 standard deviation). A 2-stage
individual participant data meta-analysis was used to assess
the association of each standardized fatty acid concentration
with study covariates (ethnicity, age, smoking, alcohol drink-
ing, and BMI); depending on the measurement scale (binary or
continuous) study-specific linear or logistic regression model
were used.
Two-stage individual participant data meta-analysis was
also used to estimate the association of baseline concentra-
tion of each fatty acid with the risk of CHD and stroke. In the
first stage, logistic regression was used to model the
exposure-outcome association for each study (except for
UKCTOCS, for which conditional logistic regression was used
to account for matching by age, recruitment center, and time
of blood sampling). In the second stage, study-specific
estimates were combined using DerSimonian & Laird random
effects model.28 Three different models were fitted: unad-
justed model (M0); minimally adjusted model (M1) (ie,
adjusted for recruitment place and typical demographic/
lifestyle confounders: age, non-European background, smok-
ing, alcohol drinking, and BMI); fully adjusted model (M2) (ie,
adjusted for variables in M1 plus other fatty acids). Adjust-
ment of M2 by the other fatty acids aimed at accounting for
the correlation in the concentration of different fatty acids,
allowing us to explore the independent effect of each fatty
acid. Some studies have expressed fatty acids in terms of
their proportion over total fatty acids. However, this approach
complicates the interpretation of findings as changes in the
proportion of each fatty acid could be related to both
numerator and denominator of the ratio.29
Heterogeneity was assessed by I2 values. To explore the
presence of effect modification on the association of fatty
acids levels and CHD or stroke risk, we carried out subgroup
analyses according to sex, European ethnicity (yes or no), age
(<65 or ≥65 years old), BMI (underweight/normal [<25 kg/
m2] or overweight/obese [≥25 kg/m2]), type of event (fatal or
nonfatal), and study design (cohort or case control). To
account for multiple testing, we used Bonferroni-corrected P
values (0.05/48=0.001) considering 48 independent tests (6
covariates94 fatty acids92 outcomes).
We also explored the presence of nonlinear effects by
modeling CHD or stroke risk in relation to standardized fatty
acids concentration using multilevel logistic regression models
with restricted cubic splines with 5 knots at percentiles 5, 25, 50,
75, and 95 of study-specific Z scores. Because of the matched
case-control design, UKCTOCS data were modeled separately
using conditional logistic regression models with restricted cubic
splines. Nonlinear models were compared with linear models
using a likelihood ratio test. Bonferroni-adjusted P<0.003 (0.05/
16 tests) were adopted as evidence of nonlinearity. The same
nonlinear models were fitted using unstandardized fatty acids
concentration (mmol/L) as a sensitivity analysis.
For all models, we conducted complete case analysis
(7392 and 8543 individuals were excluded from CHD and
stroke models, respectively), followed by multiple imputation
using Stata version 12 (StataCorp, College Park, TX). To
investigate whether the missing completely at random
assumption is likely to hold, we evaluated the association of
our complete case indicator (0=any missing; 1=no missing
variables) with baseline predictors of CHD and stroke, fatty
acids, and CHD/stroke risk using logistic regression. Impu-
tation of missing values was carried out to explore potential
biases by missing data. Multivariate imputation using chained
equations for 20 complete data sets with 10 iterations each
was used. Imputation was performed separately for each
study and included sex, age, European background, BMI,
smoking, alcohol drinking, blood lipids, glucose, systolic and
diastolic blood pressure, prevalent type 2 diabetes mellitus,
and use of lipid-lowering medication (some variables were not
available for UKCTOCS; no participant was on lipid-lowering
medication in SABRE at baseline). Coefficients and standard
DOI: 10.1161/JAHA.119.013131 Journal of the American Heart Association 3
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errors for the variability between imputations were combined
according to Rubin’s rules.30 The same models as for the
complete case analysis (M0 to M2) were fitted for each study
using the imputed data sets, and study-specific estimates




The proportion of participants who experienced CHD or stroke
events was 17.1% and 9.7%, respectively, with maximum
follow-up duration ranging from 10 to 25 years across studies
(Tables 1 and 2). At baseline, participants were 52.1% male,
89.1% of European background, and 61.1% aged 65 or
younger. Overall, SFAs were the most abundant blood fatty
acid class (mean, 4.5 mmol/L; SD, 1.2), followed by LA
(mean, 3.2 mmol/L; SD, 0.8), MUFA (mean, 3.1 mmol/L; SD,
1.0) and DHA (mean, 0.2 mmol/L; SD, 0.1) (Table 2). The
distribution of circulating fatty acids according to case-control
status for CHD and stroke can be found in Tables S1 and S2,
respectively.
Association of Circulating Fatty Acids With
Baseline Characteristics
Mean changes in circulating fatty acids (in SD units) according
to the distribution of demographic and lifestyle characteristics
and cardiovascular disease biomarkers are shown in Table S3.
Table 1. Characteristics of Participating Studies
Study Study Design Original Population Available Data Outcome Data Collection Website
BWHHS16 Cohort 4286 women aged 60–79 y
recruited from general




Biennial medical record review
(with validation checks)
Death certificates obtained from





BRHS17 Cohort 7735 men aged 40–59 y
recruited from general




Biennial medical record review
(with validation checks)
Death certificates obtained from




WHII18 Cohort 10 308 civil servants recruited
from the United Kingdom
Baseline: 1997–1999
Follow-up: 12 y*
Self-reported nonfatal events (at
all phases) supplemented by
information on coronary events
identified by research clinic
ECGs, and through verification




SABRE19 Cohort 4857 individuals from European,
Indian Asian and African
Caribbean ancestry aged 40–
69 y recruited from
workplaces and general




Identified from primary-care and
hospital records and from
participant questionnaire
responses
Death certificates obtained from
the NHS Central Registration
http://www.sabrestudy.org/
CaPS20 Cohort 2512 men aged 45–59 y from





were validated from medical








1617 CHD and 863 stroke-
matched female cases
selected for a case-control
study nested in a randomized




Nonfatal and fatal events







BRHS indicates British Regional Heart Study; BWHHS, British Women’s Heart and Health Study; CaPS, Caerphilly Prospective Study; CHD, coronary heart disease; SABRE, Southall and
Brent Revisited cohort; UKCTOCS, United Kingdom Collaborative Trial of Ovarian Cancer Screening; WHII, Whitehall-II Study.
*Maximum follow-up length in years.
†Cases were matched with controls (known not to have experienced cardiovascular events before 2010) by age, recruitment center, and time of blood sampling.
DOI: 10.1161/JAHA.119.013131 Journal of the American Heart Association 4
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On average, non-Europeans have higher LA (0.15 standard
units; 95% CI, 0.08–0.21) and lower MUFA (0.42; 95% CI,
0.67 to 0.17) and SFA (0.25; 95% CI, 0.44 to 0.06);
the opposite pattern was found among ever smokers (LA,
0.11; 95% CI, 0.16 to 0.07; MUFA, 0.30; 95% CI, 0.22–
0.37; SFA, 0.12; 95% CI, 0.04–0.21). Alcohol drinkers had
increased circulation of all fatty acids, except LA (DHA, 0.35;
95% CI, 0.20–0.49; LA, 0.08; 95% CI, 0.12 to 0.04;
MUFA, 0.18; 95% CI, 0.00–0.35; SFA, 0.11; 95% CI, 0.05–
0.17). Older individuals had higher mean circulating DHA
(0.11; 95% CI, 0.03–0.18), while overweight/obese individuals
had higher MUFA (0.37; 95% CI, 0.29–0.45) and SFA (0.26;
95% CI, 0.15–0.38).
As shown in Table S4, the correlation between fatty acids
within studies was mostly moderate except for SFA, which
was highly correlated with MUFA (rPearson=0.50–0.88;
P<0.001) and with LA (rPearson=0.16–0.71; P<0.001) in most
studies.
Association of Circulating Fatty Acids With CHD
and Stroke Risk
Complete information for fatty acids–CHD and fatty acids–
stroke analyses was available for 16 126 (3022 CHD cases)
and 14 975 (1606 stroke cases) participants, respectively.
There was some evidence of circulating DHA being associated
with lower CHD risk in the fully adjusted model (odds ratio,
0.85; 95% CI, 0.76–0.95 per standard unit increase in DHA),
and with stroke (OR for unadjusted/minimally adjusted
models, 0.93; 95% CI, 0.87–0.99; OR for fully adjusted
model, 0.95; 95% CI, 0.89–1.02). However, between-study
heterogeneity was high in CHD models for DHA (I2, 70%–85%)
(Figure 1). Higher circulating omega-6 LA was consistently
associated with lower stroke risk in all models (eg, OR for fully
adjusted model: 0.82; 95% CI, 0.75–0.90), but not associated
with CHD risk. Between-study heterogeneity was high for the
association of LA with CHD risk (I2, 79%–88%), but moderate
for its association with stroke risk (I2, 12%–42%) (Figure 1).
Higher blood MUFA was related to increased CHD risk in all
models (eg, OR for fully adjusted model, 1.36; 95% CI, 1.15–
1.61) and with increased stroke risk in the fully adjusted model
only (OR, 1.22; 95% CI, 1.03–1.44). SFA levels were related to
increased CHD risk in the unadjusted and minimally adjusted
models only (OR, 1.12; 95% CI, 1.05–1.20) and were not related
to stroke risk. Between-study heterogeneity was variable for
MUFA in both CHD (I2, 0%–70%) and strokemodels (I2, 4%–47%)
and moderate for SFA in both CHD (I2, 46%–58%) and stroke
models (I2, 29%–45%) (Figure 1).
Further details on metrics of statistical heterogeneity in the
meta-analyses are available in Tables S5 and S6. Pooled
results using fixed-effect meta-analysis (with inverse variance
weights) are also provided for comparison (Figure S1).
Subgroup Analysis and Nonlinear Effects
In the subgroup analysis for the association between polyun-
saturated fatty acids (ie, DHA and LA) and CHD risk,
heterogeneity was largely explained by study design, with
the case-control study estimating a stronger protective effect
compared with the null or slightly positive effect estimated by
the cohorts for both DHA (Pinteraction=0.0003) and LA
(Pinteraction=0.0003) (Figure 2). There was no strong evidence
of effect modification by any other variable for CHD risk
(Figure 2) and by any variable for stroke risk (Figure 3). In
addition, there was no consistent evidence of nonlinear
associations between fatty acid levels and CHD or stroke risk
(Figures S2 and S3).
Missingness
Our complete case analysis indicator was associated with CHD
risk in SABRE and UKCTOCS and with stroke risk in BWHHS and
UKCTOCS. The complete case indicator was also associated
with several circulating fatty acids in several studies (eg,
BWHHS, BRHS, and UKCTOCS) and with some of the study
covariates (Table S7). The associations of fatty acid levels with
CHD and stroke risk in complete case analysis (Figure 1) were
broadly similar to those in the imputed data (Table S8).
Discussion
Our findings indicate that circulating LA (omega-6 fatty acid)
and DHA (omega-3 fatty acid) are not robustly associated with
lower CHD risk. Although circulating DHA is related to lower
CHD risk after adjusting for other fatty acids, there is
evidence of high between-study heterogeneity and effect
modification by study design. Stroke risk was consistently
lower with increasing circulating LA and slightly lower with
increasing circulating DHA. Circulating MUFAs were associ-
ated with higher CHD risk across all models and with stroke
risk only after accounting for other fatty acids, while SFAs
were not related to increased CHD risk after accounting for
other fatty acids or to stroke risk.
Omega-3 and omega-6 fatty acids are essential nutrients,
as they cannot be produced endogenously. For this reason,
blood concentration of these fatty acids reflects both dietary
intake and metabolism and are increasingly being used as
biomarkers of their consumption31 to avoid some biases
from self-reported dietary intake. A previous meta-analysis
including 25 721 participants estimated that circulating DHA
(relative risk, 0.79; 95% CI, 0.67–0.93), but not LA (relative
risk, 0.99; 95% CI, 0.77–1.28) was associated with lower
CHD risk12 when comparing the top to the bottom tertile of
fatty acid concentration. Fewer studies have assessed the
association of blood fatty acids with stroke risk and have
DOI: 10.1161/JAHA.119.013131 Journal of the American Heart Association 5
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reported no association with circulating long chain omega-
3,11,32,33 as well as an inverse32–34 or null35 relation to LA.
The 2 largest studies reported a relative risk for stroke of
1.04 (95% CI, 0.90–1.20) comparing the top tertile of long
chain omega 3 fatty acids with the bottom (n=4096)11 and a
relative risk for stroke of 0.72 (95% CI, 0.59–0.89) per 1 SD
increase in LA (n=7450).33 Recent systematic reviews of
RCTs concluded that there is probably little or no effect of
increasing long-chain omega-3 (eg, DHA) on CHD or stroke
risk13 and that the effect of increasing omega-6 on CHD or
stroke events is unclear because of the low quality of the
evidence available.14
Previous studies hypothesized that a potential threshold
effect of omega-3 intake on CHD risk could explain inconsis-
tencies between observational studies12 and RCTs9–12 in a way
that moderate consumption could be associated with benefits
compared with low consumption in observational studies, while
adding omega-3 supplement doses to an already moderate
background could produce smaller or no effects in RCTs.36 In a
recent systematic review of RCTs, there was no suggestion of
any dose-response effect of long-chain omega-3 fatty acids on
multiple cardiovascular events.13 In addition, we and others36
found no evidence of nonlinear dose-response between circu-
lating long-chain omega-3 and CHD risk. Conversely to our
analyses, diet intake and circulating omega-3 are associated in
a nonlinear fashion, with steepest dose-response in blood
omega-3 concentration with consumption of up to 400 mg/
day, which might explain nonlinear trends between omega-3
consumption and CHD risk.36
Even-numbered SFAs (eg, 16:0, palmitic acid; and 18:0,
stearic acid) and MUFAs (eg, 16:1 n-7, palmitoleic acid; and
18:1 cis-9, oleic acid) are among the most abundant in the
blood and, therefore, are likely to be overrepresented in our
measurement.12,37–39 These fatty acids can be synthetized
endogenously, by the process known as de novo lipogenesis.
Therefore, circulating even-numbered SFAs and MUFAs tend
not to reflect dietary fatty acids intake, but nonlipid dietary
precursors of de novo lipogenesis, including carbohydrate and
alcohol intake. We observed that MUFAs were positively
associated with CHD risk in contrast to results from a previous
meta-analysis.12 It is possible that these associations could
also be reflecting underlying hepatic de novo lipogenesis
activation, which is related to increased blood triglycerides,
ectopic fat deposition, and insulin resistance.40,41 The asso-
ciation of circulating SFAs with CHD risk was attenuated when
adjusting for other fatty acids (model 2). However, this result
should be interpreted with caution because of high correlation
and interconversion between SFAs and MUFAs (eg, even-
numbered MUFAs originate from desaturation of SFAs).
Smaller previous studies have reported a positive association
between circulating MUFAs and SFAs and stroke risk,32–34
which were mostly not confirmed by our findings, although
there was some evidence for a positive association between
MUFAs and stroke risk after accounting for other fatty acids.
Table 2. Baseline Characteristics of Participants* and Incident CHD and Stroke Events
BWHHS BRHS WHII SABRE CaPS UKCTOCS Total
%
N (range) 3294–3753 3556–3796 4094–5306 2856–4442 1216–1337 1721–4884 17 782–23 518
Male 0.0 100.0 71.7 74.6 100.0 0.0 52.1
Nonwhite 0.4 0.6 0.0 51.9 0.0 3.4 10.9
Age >65 y 70.9 71.8 8.8 2.5 30.4 56.3 38.9
Smokers 11.7 13.1 16.2 45.3 82.0  26.6
Alcohol drinkers 38.7 63.2 91.0 82.5 93.0  73.4
Overweight/obese 71.9 69.8 57.5 61.2  60.2 59.7
Incident CHD event 8.4 9.0 3.8 19.2 24.5 50.1 17.1
Incident stroke event 5.8 6.2 1.6 8.8 13.8 50.1 9.7
Mean (SD)
DHA, mmol/L 0.3 (0.1) 0.2 (0.1) 0.2 (0.1) 0.1 (0) 0.1 (0) 0.2 (0.1) 0.2 (0.1)
LA, mmol/L 3.8 (0.8) 3 (0.7) 3.3 (0.6) 2.8 (0.6) 2.5 (0.7) 3.2 (0.7) 3.2 (0.8)
MUFAs, mmol/L 3.1 (1.1) 3 (0.9) 3 (0.9) 2.4 (0.7) 2.7 (1) 3.6 (1.1) 3.1 (1)
SFAs, mmol/L 4.9 (1.2) 4.2 (0.9) 4.6 (1) 3.8 (1.5) 4 (1) 4.8 (1.2) 4.5 (1.2)
BRHS indicates British Regional Heart Study; BWHHS, British Women’s Heart and Health Study; CaPS, Caerphilly Prospective Study; CHD, coronary heart disease; DHA, docosahexaenoic
acid; LA, linoleic acid; MUFAs, monounsaturated fatty acids; SABRE, Southall and Brent Revisited cohort; SFAs, saturated fatty acids; UKCTOCS, United Kingdom Collaborative Trial of
Ovarian Cancer Screening; WHII, Whitehall-II Study.
*Subjects with prevalent cardiovascular disease at baseline were excluded.
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Fatty acids are dynamic molecules capable of influencing a
wide range of cell signaling pathways and potentially modulat-
ing lipid metabolism,4,42,43 glucose homeostasis,44,45 blood
pressure,46–48 inflammatory response,49–51 and endothelial
function.48,52 The circulating fatty acids pool reflects the
dynamic contribution of multiple metabolic pathways regulated
by key hormonal signals, including adipose tissue lipolysis (the
main source of free circulating fatty acids during fasting),
hydrolysis of blood triglycerides in triglyceride-rich lipoproteins,
reesterification to triglycerides within adipocytes, and periph-
eral fatty acids utilization.53 In addition, fatty acids are
transformed into other fatty acids by processes of desaturation
and elongation. For these reasons, isolating the effect of
circulating fatty acids from other pathways is challenging in
studies of observational nature. In addition, lipoprotein traits
not only share metabolic regulation pathways with fatty acids53
but might also be downstream effects of fatty acids.4,42,44–47,49
Our findings show differences between CHD and stroke in
terms of their association with blood fatty acid levels. This
has particularly important implications in the context of
RCTs, in which the use of composite events (eg, combining
CHD and stroke) is a frequent practice to increase study
power but might in fact attenuate effect estimates toward
the null when the effect of the treatment is specific to either
CHD or stroke.
The strengths of our study include the large sample size, long
follow-up, comprehensive case ascertainment, and adjustment
for many potential confounders, as well as assessment of
nonlinear effects and effect modification by biological and
methodological features. In addition, access to individual
participant data allowed us to compare similar models across
all participating studies, unlike most meta-analyses based on
summary data. Some limitations should be highlighted such as
the measure of blood fatty acids at a single time point, which
might have introduced nondifferential measurement error and
consequently underestimated our effect estimates; the low
resolution of the nuclear magnetic resonance platform with
regard to identifying multiple fatty acids within each class
despite evidence of heterogeneous association of individual
fatty acids within omega-3, omega-6, and SFA classes with
cardiometabolic disease12,54; and the possibility of residual
confounding attributable to the complex interplay of exogenous
(diet) and endogenous (metabolism and genetics) factors,
whichwewere unable to tease out. In addition, in the analysis of
effect modification by the study covariates, some studies could
only contribute with data to one of the strata of a covariable (eg,
for the sex-stratified analysis, women-only studies such as
BWHHS and UKCTOCS contributed data only for the female
stratum), whichmight have introduced bias, as the studies differ
in other characteristics.
CHD Stroke
Figure 1. Odds ratio for coronary heart disease (CHD) and stroke according to blood fatty acids concentration. Results were pooled using
random effect meta-analysis and are expressed as odds ratio (and 95% confidence interval) per standard deviation unit increase in blood fatty
acids concentration (CHD analysis, N=3022 cases and 13 104 controls; stroke analysis, N=1606 cases and 13 369 controls). Each standard
unit corresponds to 0.06 mmol/L for DHA, 0.7 for LA, 1.0 for MUFAs, and 1.1 for SFAs. Model 0 (M0): unadjusted model; Model 1 (M1):
adjusted for recruitment place, demographic and lifestyle variables (age, sex, non-European ancestry, smoking, alcohol drinking, and body mass
index); Model 2 (M2): adjusted for variables in M1 plus other fatty acids. CHD indicates coronary heart disease; DHA, docosahexaenoic acid; FA,
fatty acid; LA, linoleic acid; MUFA, monounsaturated fatty acids; OR, odds ratio; SFA, saturated fatty acids.
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We found consistent evidence that circulating LA is
associated with lower risk of stroke and that MUFA is related
to higher risk of CHD. The different pattern between CHD and
stroke in terms of fatty acids risk profile raises a cautionary
note for studies in which composite events are used. Different
study designs (eg, clinical trials and Mendelian randomization
studies) will be needed to assess which, if any, of the
associations observed is causal.
DHA SFAMUFALA
OR FOR CHD (95% CI)
Figure 2. Odds ratio for coronary heart disease in relation to blood fatty acids concentration according to study covariates. Results are expressed
as odds ratio (and 95% CI) per SD unit increase in blood fatty acids concentration. Model was adjusted for recruitment place, demographic and
lifestyle variables (age, sex, non-European ancestry, smoking, alcohol drinking, and body mass index). UKCTOCS was excluded from the analysis
stratified by body mass index, as this was not a matching variable. Only the SABRE South Asian participants contributed to the non-European
stratum. P value for interaction threshold after Bonferroni correction=0.05/48=0.001. BMI indicates body mass index; CHD, coronary heart
disease; DHA, docosahexaenoic acid; LA, linoleic acid; MUFA, monounsaturated fatty acids; OR, odds ratio; SFA, saturated fatty acids.
DHA SFAMUFALA
OR for stroke (95% CI)
Figure 3. Odds ratio for stroke in relation to blood fatty acids concentration according to study covariates. Results are expressed as odds
ratio (and 95% CI) per SD unit increase in blood fatty acids concentration. Model was adjusted for recruitment place, demographic and lifestyle
variables (age, sex, non-European ancestry, smoking, alcohol drinking, and body mass index). UKCTOCS was excluded from the analysis
stratified by body mass index, as this was not a matching variable in the case-control design. Only the SABRE study had enough participants to
contribute to analyses in the non-Europeans stratum. P value for interaction threshold after Bonferroni correction=0.05/48=0.001. BMI
indicates body mass index; DHA, docosahexaenoic acid; LA, linoleic acid; MUFA, monounsaturated fatty acids; OR, odds ratio; SFA, saturated
fatty acids.
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Data S1. SUPPLEMENTARY METHODS 
 
Nuclear magnetic resonance (NMR) spectroscopy platform  
 The quantified metabolic measures were obtained per sample of EDTA-plasma, using 
a 1D proton (1H) NMR spectroscopy-based platform described previously 1-4. Briefly, the serum 
samples were stored in a freezer at -80oC. The frozen samples were first slowly thawed in a 
refrigerator (+4oC) overnight prior to metabolomics profiling. 260 µL plasma and 260 µL 
sodium phosphate buffer (75 mM Na2HPO4, 0.08% sodium 3-(trimethylsilyl)propionate-
2,2,3,3-d4, 0.04% sodium azide in 80%/20% H20/D2O, pH 7.4) were mixed and transferred 
to NMR tubes using an 8-channel, Varispan Janus liquid handling robot (PerkinElmer). NMR 
spectra were acquired using a Bruker Avance III HD 500MHz spectrometer with a room 
temperature 5mm, inverse triple resonance TXI probe and a Bruker Avance III HD 600MHz 
spectrometer equipped with a nitrogen-cooled triple resonance probe (CryoProbe Prodigy 
TCI). Both spectrometers were equipped with SampleJet auto-samplers with cooled (6°C) 
sample storage. Spectra were acquired using standardized parameters using three NMR 
experiments or ‘molecular windows’ to characterize lipoproteins, low molecular weight 
metabolites and lipids. Lipid spectra were acquired after a standardised lipid extraction 
procedure performed on each sample using a VIAFLO 96 channel electronic pipette (Integra 
Biosciences). The quantified fatty acids used in this study correspond to all forms of fatty acids 
present in the circulation (i.e. all the fatty acids in triglycerides, phospholipids, or cholesterol 
esters, or as free fatty acids). Data pre-processing and quantification were as previously 
described 1-4. The NMR spectra were analysed for absolute quantification using regression 
models 5. There is a high analytical consistency, in epidemiological settings, between 
metabolic measures quantified by the NMR metabolomics platform and the concentrations 
obtained from routine clinical chemistry 6, and other analytical methods, such as gas 
chromatography 6, 7 and enzymatic method 6, with correlations >0.9. In addition, the 
consistency of biomarker associations with disease incidence for metabolic traits quantified 
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SUPPLEMENTARY TABLES AND FIGURES 
Table S1. Distribution of fatty acids (mean and standard error) according to coronary heart disease (CHD) status and study 
 BWHHS BWHHS BRHS BRHS WHII WHII SABRE SABRE CaPS CaPS UKCTOCS UKCTOCS 
Mean (SD) 
 Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
DHA (mmol/L) 0.3 (0.09) 0.3 (0.08) 0.15 (0.05) 0.16 (0.06) 0.19 (0.06) 0.19 (0.07) 0.14 (0.04) 0.14 (0.04) 0.12 (0.04) 0.11 (0.04) 0.18 (0.06) 0.2 (0.07) 
LA (mmol/L) 3.77 (0.92) 3.77 (0.8) 3.02 (0.66) 2.99 (0.64) 3.45 (0.65) 3.33 (0.64) 2.8 (0.62) 2.77 (0.6) 2.6 (0.68) 2.46 (0.67) 3.09 (0.72) 3.22 (0.69) 
MUFA (mmol/L) 3.44 (1.25) 3.06 (1.08) 3.1 (0.87) 3.01 (0.85) 3.26 (0.86) 2.97 (0.86) 2.47 (0.75) 2.4 (0.71) 2.85 (0.98) 2.66 (0.97) 3.72 (1.15) 3.56 (1.07) 
SFA (mmol/L) 5.08 (1.37) 4.88 (1.17) 4.22 (0.93) 4.16 (0.87) 4.92 (0.93) 4.64 (0.96) 3.92 (1.66) 3.77 (1.56) 4.21 (1.01) 3.99 (1.04) 4.85 (1.19) 4.84 (1.13) 
Results based on complete case analysis (N = 3,022 CHD cases and 13,104 controls). DHA: docosahexaenoic acid; LA: linoleic acid; MUFA: monounsaturated fatty acids; SFA: saturated 
fatty acids. BWHHS: British Women’s Heart and Health Study; BRHS: British Regional Heart Study; WHII: Whitehall-II Study; SABRE: Southall And Brent REvisited cohort; UKCTOCS: 
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Table S2. Distribution of fatty acids (mean and standard error) according to stroke status and study 
  BWHHS BWHHS BRHS BRHS WHII WHII SABRE SABRE CaPS CaPS UKCTOCS UKCTOCS 
Mean (SD) 
 Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
DHA (mmol/L) 0.3 (0.09) 0.3 (0.08) 0.15 (0.06) 0.16 (0.06) 0.19 (0.08) 0.19 (0.07) 0.14 (0.04) 0.14 (0.04) 0.12 (0.05) 0.11 (0.04) 0.19 (0.06) 0.19 (0.06) 
LA (mmol/L) 3.74 (0.84) 3.77 (0.81) 2.87 (0.66) 3 (0.64) 3.08 (0.66) 3.34 (0.64) 2.69 (0.64) 2.79 (0.6) 2.47 (0.63) 2.5 (0.68) 3.06 (0.7) 3.19 (0.69) 
MUFA (mmol/L) 3.21 (1.27) 3.08 (1.09) 2.94 (0.83) 3.02 (0.85) 2.81 (0.79) 2.98 (0.86) 2.48 (0.76) 2.41 (0.71) 2.77 (1.02) 2.7 (0.97) 3.53 (1.12) 3.48 (1.03) 
SFA (mmol/L) 4.98 (1.37) 4.89 (1.18) 4.04 (0.92) 4.18 (0.87) 4.44 (0.9) 4.66 (0.96) 3.88 (2.01) 3.79 (1.51) 4.06 (0.99) 4.04 (1.05) 4.69 (1.12) 4.78 (1.07) 
Results based on complete case analysis (N = 1,606 stroke cases and 13,369 controls). DHA: docosahexaenoic acid; LA: linoleic acid; MUFA: monounsaturated fatty acids; SFA: 
saturated fatty acids. BWHHS: British Women’s Heart and Health Study; BRHS: British Regional Heart Study; WHII: Whitehall-II Study; SABRE: Southall And Brent REvisited cohort; 
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Table S3. Association of blood fatty acids concentration with demographic and lifestyle factors 
  N DHA LA MUFA SFA 
  (range) Beta 95% CI p I2 Beta 95% CI p I2 Beta 95% CI p I2 Beta 95% CI p I2 
Non-European 19,928-20,025 -0.02 -0.46 0.42 0.925 95 0.15 0.08 0.21 6E-06 0 -0.42 -0.67 -0.17 0.001 83 -0.25 -0.44 -0.06 0.009 70 
Age (> 65 years) 20,047-20,144 0.11 0.03 0.18 0.006 78 -0.01 -0.08 0.05 0.731 69 -0.02 -0.07 0.04 0.522 55 -0.02 -0.08 0.05 0.607 66 
Ever smokers 14,828-14,888 -0.05 -0.28 0.17 0.642 96 -0.11 -0.16 -0.07 1E-07 0 0.30 0.22 0.37 3E-13 70 0.12 0.04 0.21 0.006 76 
Alcohol drinkers 14,906-14,965 0.35 0.2 0.49 3E-06 92 -0.08 -0.12 -0.04 7E-05 0 0.18 0.00 0.35 0.053 95 0.11 0.05 0.17 0.001 56 
Overweight/obese 19,402-19,498 0.04 -0.03 0.11 0.270 83 0.02 -0.04 0.08 0.475 72 0.37 0.29 0.45 0.000 87 0.26 0.15 0.38 9E-06 94 
Beta: study- and sex-specific standard deviation units of blood fatty acids concentration according to study covariates. DHA: docosahexaenoic acid; LA: linoleic acid; MUFA: monounsaturated 
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Table S4. Correlation across circulating fatty acids 
 DHA LA MUFA 
 BWHHS BRHS WHII SABRE CaPS UKCTOCS BWHHS BRHS WHII SABRE CaPS UKCTOCS BWHHS BRHS WHII SABRE CaPS UKCTOCS 
DHA 1 1 1 1 1 1             
LA 0.49 0.36 0.28 0.36 0.40 0.32 1 1 1 1 1 1       
MUFA 0.36 0.36 0.40 0.42 0.45 0.30 0.42 0.45 0.51 0.38 0.43 0.51 1 1 1 1 1 1 
SFA 0.52 0.45 0.42 0.25 0.53 0.37 0.67 0.70 0.71 0.16 0.71 0.68 0.82 0.86 0.88 0.50 0.86 0.88 
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Table S5. Pooled estimates and heterogeneity metrics for meta-analysis of the association of circulating fatty acids with risk of coronary heart disease 
Fatty acid Model OR OR - 95% CI P Cochrane's Q df P for Cochrane's Q I2 I2 - 95% reference interval* 
DHA M0 0.92 0.82 1.04 0.206 30 5 1.21E-05 84 66 92 
DHA M1 0.94 0.82 1.07 0.340 32 5 4.80E-06 85 68 93 
DHA M2 0.85 0.76 0.95 0.005 17 5 0.005 70 29 87 
LA M0 1.05 0.92 1.20 0.480 40 5 1.48E-07 88 75 94 
LA M1 1.05 0.92 1.20 0.451 40 5 1.87E-07 87 75 94 
LA M2 1.01 0.87 1.18 0.854 24 5 2.36E-04 79 54 90 
MUFA M0 1.20 1.12 1.28 2E-07 11 5 0.047 55 0 82 
MUFA M1 1.18 1.13 1.24 4E-13 4 5 0.609 0 0 75 
MUFA M2 1.36 1.15 1.61 4E-04 17 5 0.005 70 31 87 
SFA M0 1.12 1.05 1.20 0.001 12 5 0.035 58 0 83 
SFA M1 1.12 1.05 1.20 0.001 10 5 0.065 52 0 81 
SFA M2 0.94 0.82 1.09 0.421 9 5 0.100 46 0 79 
Model 0 (M0): unadjusted model; Model 1 (M1): adjusted for recruitment place, demographic and lifestyle variables (age, sex, non-European ancestry, smoking, alcohol and body mass index); 
Model 2 (M2): adjusted for variables in M1 plus other fatty acids. DHA: docosahexaenoic acid; LA: linoleic acid; MUFA: monounsaturated fatty acids; SFA: saturated fatty acids. * I2 and its 95% 
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Table S6. Pooled estimates and heterogeneity metrics for meta-analysis of the association of circulating fatty acids with risk of stroke 
Fatty acid Model OR OR - 95% CI P Cochrane's Q df P for Cochrane's Q I2 I2 - 95% reference interval* 
DHA M0 0.93 0.87 0.99 0.022 4.0 5 0.554 0 0 75 
DHA M1 0.93 0.87 0.99 0.016 4.8 5 0.447 0 0 75 
DHA M2 0.95 0.89 1.02 0.165 3.4 5 0.641 0 0 75 
LA M0 0.85 0.78 0.92 1E-04 8.4 5 0.136 40 0 76 
LA M1 0.85 0.78 0.93 2E-04 8.7 5 0.124 42 0 77 
LA M2 0.82 0.75 0.90 3E-05 5.7 5 0.339 12 0 78 
MUFA M0 1.03 0.96 1.12 0.405 7.6 5 0.182 34 0 73 
MUFA M1 1.04 0.98 1.11 0.186 5.2 5 0.390 4 0 76 
MUFA M2 1.22 1.03 1.44 0.022 9.4 5 0.092 47 0 79 
SFA M0 0.96 0.88 1.04 0.308 9.1 5 0.104 45 0 78 
SFA M1 0.96 0.89 1.04 0.353 7.0 5 0.220 29 0 71 
SFA M2 0.94 0.79 1.11 0.451 7.6 5 0.178 34 0 74 
Model 0 (M0): unadjusted model; Model 1 (M1): adjusted for recruitment place, demographic and lifestyle variables (age, sex, non-European ancestry, smoking, alcohol and body mass index); 
Model 2 (M2): adjusted for variables in M1 plus other fatty acids. DHA: docosahexaenoic acid; LA: linoleic acid; MUFA: monounsaturated fatty acids; SFA: saturated fatty acids. * I2 and its 95% 
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Figure S1. Odds ratio for coronary heart disease (CHD) and stroke according to blood fatty acids concentration (fixed effects meta-analysis) 
Results were pooled using fixed effect meta-analysis and are expressed as odds ratio (and 95% confidence interval) per standard deviation unit increase in blood fatty acids 
concentration. Each standard unit corresponds to approximately 0.06 mmol/L for DHA, 0.7 for LA, 1.0 for MUFA, and 1.1 for SFA. Model 0 (M0): unadjusted model; Model 1 
(M1): adjusted for recruitment place, demographic and lifestyle variables (age, sex, non-European ancestry, smoking, alcohol and body mass index); Model 2 (M2): adjusted 
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Figure S2. Dose-response curve for the association between blood fatty acids and coronary heart disease (CHD) risk 
Results are expressed as odds ratio (and 95% confidence interval) according blood fatty acids concentration in standard deviation units. Each standard unit corresponds to 
approximately 0.06 mmol/L for DHA, 0.7 for LA, 1.0 for MUFA, and 1.1 for SFA. Models were adjusted for recruitment place, demographic and lifestyle variables (age, sex, 
non-European ancestry, smoking, alcohol and body mass index). P-value for the comparison between linear and nonlinear (restricted cubic spline) models were derived from 
the likelihood-ratio test. P-value threshold after Bonferroni correction = 0.05/16 = 0.003. DHA: docosahexaenoic acid; LA: linoleic acid; MUFA: monounsaturated fatty acids; 
SFA: saturated fatty acids. The relations of the fatty acids with CHD risk were also modelled using blood fatty acids concentration in mmol/L (not in study-specific standard 
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Figure S3. Dose-response curve for the association between blood fatty acids and stroke risk 
Results are expressed as odds ratio (and 95% confidence interval) according blood fatty acids concentration in standard deviation units. Each standard unit corresponds to 
approximately 0.06 mmol/L for DHA, 0.7 for LA, 1.0 for MUFA, and 1.1 for SFA. Models were adjusted for recruitment place, demographic and lifestyle variables (age, sex, 
non-European ancestry, smoking, alcohol and body mass index). P-value for the comparison between linear and nonlinear (restricted cubic spline) models were derived from 
the likelihood-ratio test. P-value threshold after Bonferroni correction = 0.05/16 = 0.003. DHA: docosahexaenoic acid; LA: linoleic acid; MUFA: monounsaturated fatty acids; 
SFA: saturated fatty acids. The relations of the fatty acids with stroke risk were also modelled using blood fatty acids concentration in mmol/L (not in study-specific standard 
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Table S7. P-value for the association between the complete case indicator for CHD or stroke analyses and study variables 

























Age (y) 8.83E-05 8.83E-05 0.33 0.33 0.61 0.09 0.01 3.57E-03 2.17E-04 2.17E-04 0.90 0.07 
Sex — — — — 0.47 0.49 5.04E-76 1.11E-74 — — — — 
European ancestry 0.93 0.93 0.41 0.41 — — 6.48E-36 1.30E-34 — — 0.17 — 
Smoking 1.55E-05 1.55E-05 0.82 0.82 2.67E-08 1.79E-05 0.69 0.63 0.95 0.95 — — 
Alcohol drinking 0.38 0.38 0.48 0.48 0.47 0.08 2.96E-21 6.20E-20 0.27 0.27 — — 
BMI 1.52E-05 1.52E-05 3.60E-04 3.60E-04 0.01 1.94E-03 4.74E-06 4.29E-06 — — 0.53 0.90 
DHA 3.47E-04 3.47E-04 8.18E-04 8.18E-04 0.53 0.67 0.15 0.32 9.90E-05 9.90E-05 8.39E-07 3.82E-05 
LA 3.06E-03 3.06E-03 0.25 0.25 0.63 0.55 0.16 0.11 0.96 0.96 3.20E-04 1.09E-07 
MUFA 1.17E-07 1.17E-07 1.04E-03 1.04E-03 0.05 0.05 0.95 0.78 0.35 0.35 2.01E-03 2.62E-05 
SFA 1.54E-06 1.54E-06 2.99E-03 2.99E-03 0.27 0.27 0.30 0.61 0.49 0.49 4.56E-05 1.02E-07 
CHD 0.03 — 0.89 — 0.16 — 1.69E-15 — 0.11 — 1.04E-04 — 
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 Table S8. Odds ratio for coronary heart disease (CHD) and stroke according to blood fatty acids concentration after multiple imputation 
  
CHD Stroke 
OR 95% CI OR 95% CI 
DHA     
M0 0.92 (0.82; 1.03) 0.94 (0.89; 1.00) 
M1 0.95 (0.83; 1.08) 0.94 (0.88; 0.99) 
M2 0.87 (0.77; 0.97) 0.96 (0.90; 1.03) 
LA     
M0 1.03 (0.90; 1.17) 0.86 (0.80; 0.92) 
M1 1.03 (0.90; 1.17) 0.86 (0.80; 0.93) 
M2 0.98 (0.86; 1.12) 0.82 (0.76; 0.89) 
MUFA     
M0 1.19 (1.11; 1.27) 1.04 (0.98; 1.11) 
M1 1.17 (1.12; 1.22) 1.04 (0.98; 1.11) 
M2 1.35 (1.14; 1.61) 1.18 (1.00; 1.40) 
SFA     
M0 1.12 (1.04; 1.20) 0.97 (0.89; 1.05) 
M1 1.11 (1.03; 1.20) 0.97 (0.90; 1.05) 
M2 0.93 (0.80; 1.09) 0.96 (0.82; 1.12) 
Results are expressed as odds ratio (and 95% confidence interval) per standard deviation unit increase in blood fatty acids concentration. Model 0 (M0): unadjusted model; 
Model 1 (M1): adjusted for recruitment place, demographic and lifestyle variables (age, sex, non-European ancestry, smoking, alcohol and body mass index); Model 2 (M2): 
adjusted for variables in M1 plus other fatty acids. DHA: docosahexaenoic acid; LA: linoleic acid; MUFA: monounsaturated fatty acids; SFA: saturated fatty acids; CHD: coronary 
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